Citi analyst David Lebowitz lowered the firm’s price target on Pliant Therapeutics to $44 from $45 and keeps a Buy rating on the shares post the Q1 report. The firm says the company’s pipeline progress is on track.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics, Inc. (PLRX) Q1 Earnings Cheat Sheet
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics announces accelerated bexotegrast development plan
Questions or Comments about the article? Write to editor@tipranks.com